$SPRCSep 2, 2026, 12:18 PMAI processed
SciSparc unit pursues FDA orphan status for Tourette drug, hires RK Strategies
AI Summary
SciSparc's majority-owned NeuroThera is pursuing FDA Orphan Drug Designation for SCI-110 (adult Tourette syndrome) and has retained RK Strategies to support U.S. government and public affairs engagement. SCI-110 is a cannabinoid-based combo now in a Phase IIb program at Yale, Hannover and Tel Aviv after a Phase IIa that showed an average 21% tic reduction, so orphan status could boost regulatory/commercial profile but clinical benefit remains preliminary.
Positives
- NeuroThera is formally pursuing FDA Orphan Drug Designation for SCI-110 (adult Tourette syndrome).
- SCI-110 has advanced into a multicenter Phase IIb program at Yale, Hannover Medical School and Tel Aviv Sourasky Medical Center.
- Phase IIa reported an average 21% reduction in tic scores, providing an early efficacy signal.
Negatives
- Orphan Drug Designation is not granted yet and remains uncertain.
- Phase IIa efficacy was modest (≈21% mean tic reduction) and represents preliminary data from a small study.
- Regulatory and commercial outcomes depend on ongoing Phase IIb results and further evidence.